Cognition Therapeutics aligns with FDA on Phase 3 zervimesine DLB trial

Cognition Therapeutics has secured FDA alignment on trial design for a pivotal Phase 3 study of zervimesine in dementia with Lewy bodies, a condition with

An amber IV bag hangs above an infusion pump in the foreground, with a brightly lit medical treatment room containing multiple beige recliners and a large window blurred in the background.

Cognition Therapeutics has reached agreement with the US Food and Drug Administration on the key design parameters of a registrational Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies (DLB), the NASDAQ-listed clinical-stage company announced on 22 October 2026.

The planned study will enrol patients with mild-to-moderate DLB, who will be randomised to receive either 100 mg of once-daily oral zervimesine or placebo over nine months. The FDA's Divisions of Neurology and Psychiatry within the Office of Neuroscience both participated in the alignment discussions, which covered patient selection, dosing, trial duration, and endpoints.

Trial design and endpoints

The primary endpoint will be the Neuropsychiatric Inventory measuring hallucinations and delusions (NPI-2), a choice the company says reflects the measurability of psychotic symptoms in DLB. A key secondary endpoint will be the Alzheimer's Disease Cooperative Study Activities of Daily Living scale, assessing functional impact.

Anthony Caggiano, chief medical officer at Cognition, explained the rationale: "Hallucinations occur in a majority of people with DLB, often occur early in disease, and typically worsen as the disease progresses. We believe their presence in early stages and predictable decline means that changes in psychosis may serve as a proxy for changes in underlying disease."

The decision to anchor the primary endpoint on neuropsychiatric symptoms, rather than a cognitive composite, reflects the practical challenge of tracking DLB progression: unlike Alzheimer's disease, DLB currently has no approved blood-based biomarker, making objective staging difficult.

Zervimesine is a sigma-2 receptor modulator designed to displace toxic oligomers from synapses. It completed a Phase 2 study in DLB (the SHIMMER trial), which the company says showed a slowing of neuropsychiatric, cognitive, motor, and functional symptom progression. Cognition has not published full peer-reviewed data from SHIMMER, and investors will be looking for that dataset to be made available ahead of or alongside the Phase 3 launch. The drug has also been studied in mild-to-moderate Alzheimer's disease and geographic atrophy, and a Phase 2 study in early Alzheimer's and mild cognitive impairment (the START study) is ongoing.

Market context and competitive landscape

DLB is the second most common cause of dementia after Alzheimer's disease, affecting an estimated 1.4 million Americans, though Cognition notes that more than half of cases are believed to go undiagnosed in life, suggesting the true prevalence may be considerably higher. Despite this burden, no drug has received regulatory approval specifically for DLB, leaving a substantial unmet need.

The DLB development field has historically been thin compared with Alzheimer's, though the recent wave of anti-amyloid approvals in Alzheimer's disease has renewed interest in adjacent neurodegeneration targets. Cognition's mechanism, targeting toxic oligomers rather than amyloid plaques directly, positions it distinctly from the anti-amyloid monoclonal antibodies that now dominate late-stage Alzheimer's investment. Whether that differentiation translates into a clearer regulatory and commercial path in DLB remains to be seen, but FDA alignment on a registrational design removes a significant early uncertainty.

Cognition's development programme has been funded substantially by non-dilutive capital: the company reports nearly $200 million in grants from the National Institutes of Health and related foundations, which has allowed it to advance zervimesine with limited equity raises to date. The company is completing the Phase 3 protocol and has not announced a start date or a timeline to first patient enrolment.